#China #Cambridge #Insilico Medicine #AI Drug Discovery #Conference Call

Insilico Medicine to Conduct Earnings Conference Calls

Insilico Medicine, a notable player in the realm of generative artificial intelligence-driven drug discovery, has recently disclosed important dates for its 2026 interim earnings conference calls. The company, traded under the stock symbol HKEX: 3696, is gearing up to share its financial results for the six months concluding on June 30, 2026, alongside a business update that many investors and industry analysts look forward to.

The English-language session is slated for 8:00 PM Beijing Time on August 26, 2026, which corresponds to 8:00 AM U.S. Eastern Time on the same day. For those interested in the Mandarin session, it will take place at 9:00 AM Beijing Time on August 27, 2026 (or 9:00 PM U.S. Eastern Time on August 26, 2026). This format allows for accessibility across different time zones, reinforcing Insilico's commitment to transparency and investor relations.

Accessing the Conference Calls

Participants can join the conference calls through specific links provided by Insilico Medicine:

• - English Session: Live Webcast Link.
• - For those seeking to engage live during the discussion, they are encouraged to register through the Live Teleconference Call Link. Registration will yield further details, including dial-in numbers and a unique access PIN for phone participation.

• - Mandarin Session: The corresponding details for the Mandarin conference can be found via this Live Webcast Link. Alternate dial-in information is also available for various regions, ensuring broad accessibility. Key numbers include:

- Mainland China: +86-4001888938
- International: +86-01053827720
- United States: +1-2087016888
- Singapore: +65-31389722
- Taiwan: +886-277083288
- Hong Kong: +852-51089680
- Password: 142221

What to Expect

During these calls, attendees can anticipate discussions not only surrounding the financial metrics of the company but also insights into its ongoing initiatives, recent achievements, and future endeavors. Given Insilico's innovative approach to leveraging AI in the drug discovery process, the discussions are expected to revolve around how these advancements are potentially shaping the future of pharmaceuticals and healthcare.

Replay Availability

For those unable to attend live, a replay of the English session will shortly be available post-call, allowing stakeholders to stay informed through the company's website at Insilico.

As the landscape of medicine continues to evolve with technology at its core, Insilico Medicine is poised to share critical insights during this event, making it a must-attend for investors and industry analysts alike.

In summary, these calls not only reflect Insilico Medicine’s transparent communication strategy but also highlight its progress in pioneering AI technologies within the healthcare sector.